The evidence strength of a meta-analysis of aspirin for primary prevention of cancer
- 37 Downloads
Dr. Tarek Haykal et al. (145:1795–1809, 2019) reported a meta-analysis of aspirin for the primary prevention of cancer in individuals without known cancer. The authors found that aspirin use was not associated with significant reduction in cancer mortality or incidence, but with higher rates of bleeding. The findings of this study added some evidence to the clinical practice. However, several issues might have compromised the strength of the evidence of this systematic review. If the investigators could have further clarified the inclusion and exclusion criteria, included all eligible studies, extracted data more meticulously, and performed more necessary sensitivity analyses to confirm the robustness of their findings, the strength of evidence of this meta-analysis would have been stronger.
KeywordsLetter to the editors Evidence Strength Meta-analysis Aspirin Primary prevention Cancer
This work was funded by The Science and Technology Development Fund, Macau SAR (File No. 130/2017/A3, 0099/2018/A3, 0096/2018/A3).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE (2013) Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159:77–85. https://doi.org/10.7326/0003-4819-159-2-201307160-00002 CrossRefPubMedPubMedCentralGoogle Scholar
- Critical Leg Ischaemia Prevention Study G, Catalano M, Born G, Peto R (2007) Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 261:276–284. https://doi.org/10.1111/j.1365-2796.2006.01763.x CrossRefGoogle Scholar
- Hansson L, HOT Study Group et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351:1755–1762. https://doi.org/10.1016/s0140-6736(98)04311-6 CrossRefPubMedGoogle Scholar
- Higgins JGS (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. (2011)Google Scholar
- Hull MA et al (2018) Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 x 2 factorial trial. Lancet 392:2583–2594. https://doi.org/10.1016/s0140-6736(18)31775-6 CrossRefPubMedPubMedCentralGoogle Scholar
- The Coronary Drug Project Research Group (1980) Aspirin in coronary heart disease. Circulation 62:V59–V62Google Scholar